In conclusion, our results identify how, in colon cancer cells, the oncogenic mutation in KRAS and deletion of tumor suppressor TP53 rewire cancer metabolism and, in particular, how they co-operate in this system, to alter cytosolic and mitochondrial bioenergetics. The gene discussed is KRAS; the disease is colonic neoplasm.